Cargando…
Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy
The immune response elicited by the protective whole-cell pertussis (wP) versus the less-protective acellular pertussis (aP) vaccine has been well characterized; however, important clinical problems remain unsolved, as the inability of the currently administered aP vaccine is resulting in the reemer...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154976/ https://www.ncbi.nlm.nih.gov/pubmed/32322598 http://dx.doi.org/10.1155/2020/8202067 |
_version_ | 1783521935607463936 |
---|---|
author | da Silva Antunes, Ricardo Quiambao, Lorenzo G. Sutherland, Aaron Soldevila, Ferran Dhanda, Sandeep Kumar Armstrong, Sandra K. Brickman, Timothy J. Merkel, Tod Peters, Bjoern Sette, Alessandro |
author_facet | da Silva Antunes, Ricardo Quiambao, Lorenzo G. Sutherland, Aaron Soldevila, Ferran Dhanda, Sandeep Kumar Armstrong, Sandra K. Brickman, Timothy J. Merkel, Tod Peters, Bjoern Sette, Alessandro |
author_sort | da Silva Antunes, Ricardo |
collection | PubMed |
description | The immune response elicited by the protective whole-cell pertussis (wP) versus the less-protective acellular pertussis (aP) vaccine has been well characterized; however, important clinical problems remain unsolved, as the inability of the currently administered aP vaccine is resulting in the reemergence of clinical disease (i.e., whooping cough). Strong evidence has shown that original, childhood aP and wP priming vaccines provide a long-lasting imprint on the CD4+ T cells that impacts protective immunity. However, aP vaccination might prevent disease but not infection, which might also affect the breadth of responses to Bordetella pertussis (BP) antigens. Thus, characterizing and defining novel targets associated with T cell reactivity are of considerable interest. Here, we compare the T cell reactivity of original aP and wP priming for different antigens contained or not contained in the aP vaccine and define the basis of a full-scale genomic map of memory T cell reactivity to BP antigens in humans. Our data show that the original priming after birth with aP vaccines has higher T cell reactivity than originally expected against a variety of BP antigens and that the genome-wide mapping of BP using an ex vivo screening methodology is feasible, unbiased, and reproducible. This could provide invaluable knowledge towards the direction of a new and improved pertussis vaccine design. |
format | Online Article Text |
id | pubmed-7154976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-71549762020-04-22 Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy da Silva Antunes, Ricardo Quiambao, Lorenzo G. Sutherland, Aaron Soldevila, Ferran Dhanda, Sandeep Kumar Armstrong, Sandra K. Brickman, Timothy J. Merkel, Tod Peters, Bjoern Sette, Alessandro J Immunol Res Research Article The immune response elicited by the protective whole-cell pertussis (wP) versus the less-protective acellular pertussis (aP) vaccine has been well characterized; however, important clinical problems remain unsolved, as the inability of the currently administered aP vaccine is resulting in the reemergence of clinical disease (i.e., whooping cough). Strong evidence has shown that original, childhood aP and wP priming vaccines provide a long-lasting imprint on the CD4+ T cells that impacts protective immunity. However, aP vaccination might prevent disease but not infection, which might also affect the breadth of responses to Bordetella pertussis (BP) antigens. Thus, characterizing and defining novel targets associated with T cell reactivity are of considerable interest. Here, we compare the T cell reactivity of original aP and wP priming for different antigens contained or not contained in the aP vaccine and define the basis of a full-scale genomic map of memory T cell reactivity to BP antigens in humans. Our data show that the original priming after birth with aP vaccines has higher T cell reactivity than originally expected against a variety of BP antigens and that the genome-wide mapping of BP using an ex vivo screening methodology is feasible, unbiased, and reproducible. This could provide invaluable knowledge towards the direction of a new and improved pertussis vaccine design. Hindawi 2020-04-02 /pmc/articles/PMC7154976/ /pubmed/32322598 http://dx.doi.org/10.1155/2020/8202067 Text en Copyright © 2020 Ricardo da Silva Antunes et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article da Silva Antunes, Ricardo Quiambao, Lorenzo G. Sutherland, Aaron Soldevila, Ferran Dhanda, Sandeep Kumar Armstrong, Sandra K. Brickman, Timothy J. Merkel, Tod Peters, Bjoern Sette, Alessandro Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy |
title | Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy |
title_full | Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy |
title_fullStr | Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy |
title_full_unstemmed | Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy |
title_short | Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy |
title_sort | development and validation of a bordetella pertussis whole-genome screening strategy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154976/ https://www.ncbi.nlm.nih.gov/pubmed/32322598 http://dx.doi.org/10.1155/2020/8202067 |
work_keys_str_mv | AT dasilvaantunesricardo developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT quiambaolorenzog developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT sutherlandaaron developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT soldevilaferran developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT dhandasandeepkumar developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT armstrongsandrak developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT brickmantimothyj developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT merkeltod developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT petersbjoern developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy AT settealessandro developmentandvalidationofabordetellapertussiswholegenomescreeningstrategy |